News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celtic Pharma Licenses Targeted Drug Delivery Technology From IDEA AG


2/23/2006 2:11:29 PM

Celtic Pharmaceutical Holdings LP (“Celtic Pharma”), the international private equity firm focused on the biotechnology and pharmaceutical industries, and Munich-based IDEA AG (“IDEA”) today announce that a Celtic Pharma subsidiary, TDT, has acquired an exclusive global license to IDEA’s Transfersome® targeted delivery technology, including global rights to all IDEA’s products in clinical and pre-clinical development except for IDEA’s lead product, IDEA-033, an NSAID indicated against “deep pain”, which IDEA will continue to develop independently of TDT.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES